A medicine used to treat psoriasis worsens asthma symptoms in patients with severe asthma, according to a randomized, placebo-controlled, double-blind, clinical trial result published in the New England Journal of Medicine. The drug risankizumab, a humanized, monoclonal antibody, targets the proinflammatory cytokine IL-23. IL-23 inhibition has been an effective treatment strategy for psoriasis and Crohn’s disease. Molecular profiling of sputum samples showed the drug reduced factors that prevent infections in airways.
Fortuitous research probing the reasons why patients with rheumatoid arthritis do not get Alzheimer’s disease, has led researchers to identify an FDA approved natural protein, Sargramostim/GM-CSF, as a drug that can be repurposed to improve cognition and reduce brain amyloid, tangles, neurodegeneration, and blood biomarkers of Alzheimer's disease.